Amikacin and Cephalothin: Empiric Regimen for Granulocytopenic Cancer Patients
AUTOR(ES)
Hahn, Davis M.
RESUMO
Amikacin (15 mg/kg per day) was used in combination with cephalothin (7 g/m2 per day) as an empiric regimen for de novo febrile (>101°F [38.3°C]) episodes in 93 granulocytopenic (<1,000/mm3) cancer patients. Both drugs were given intravenously in four equal doses every 6 h. The response rate for all documented infections was 83%, including 11 of 17 (65%) bacteremias. Escherichia coli (14 cases) was the most common pathogen, whereas Pseudomonas aeruginosa (2 cases) caused fewer infections. Mean amikacin serum levels were 8.7 μg/ml at 1 h and 2.2 μg/ml at 5 h. Failure of bone marrow recovery in association with a bacteremia was a bad prognostic sign (only two of eight improving). Ototoxicity occurred in two (2%) patients, whereas presumed antibiotic-induced nephrotoxicity developed in six (7%) patients. Surveillance cultures (nose, gums axilla, and rectum) of all hospitalized patients revealed no significant change in the incidence of amikacin resistance. The combination of amikacin and cephalothin in this dose and schedule was safe and efficacious in these granulocytopenic patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=429987Documentos Relacionados
- Ticarcillin in Combination with Cephalothin or Gentamicin as Empiric Antibiotic Therapy in Granulocytopenic Cancer Patients
- Empiric Therapy for Cancer Patients: Comparative Study of Ticarcillin-Tobramycin, Ticarcillin-Cephalothin, and Cephalothin-Tobramycin
- Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
- Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients.
- Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.